Direct and quantitative evaluation of the human CYP3A4 contribution (f_m) to drug clearance using the in vitro SILENSOMES model

References

• Böttiger Y, Tybring G, Götharson E, Bertilsson L. (1997). Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmaco. Ther 62:384–91
   PubMed Web of Science ®Google Scholar
• Boyce MJ, Baisley KJ, Warrington SJ. (2012). Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 73:411–21
   PubMed Web of Science ®Google Scholar
• Burt HJ, Pertinez H, Säll C, et al. (2012). Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4. Drug Metab Dispos Biol Fate Chem 40:1658–67
   PubMed Web of Science ®Google Scholar
• Crespi CL, Penman BW. (1997). Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug–drug interactions. Adv Pharmacol San Diego CA 43:171–88
   PubMedGoogle Scholar
• Crewe HK, Barter ZE, Yeo KR, Rostami-Hodjegan A. (2011). Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos 32:303–18
   PubMed Web of Science ®Google Scholar
• Deb S, Chin MY, Adomat H, Guns EST. (2014). Ginsenoside-mediated blockade of 1α,25-dihydroxyvitamin D3 inactivation in human liver and intestine in vitro. J Steroid Biochem Mol Biol 141:94–103
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. (2007). Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica Fate Foreign Compd Biol Syst 37:986–99
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Thummel KE, Shen DD, Kunze KL. (1999). Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos Biol Fate Chem 27:180–7
   PubMed Web of Science ®Google Scholar
• Hashizume T, Mise M, Terauchi Y, et al. (1998). N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos Biol Fate Chem 26:566–71
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Cao G, et al. (1998). Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother 42:2784–91
   PubMed Web of Science ®Google Scholar
• Jerling M, Huan BL, Leung K, et al. (2005). Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 45:422–33
   PubMed Web of Science ®Google Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27
   PubMed Web of Science ®Google Scholar
• Kim KA, Chung J, Jung DH, Park JY. (2004). Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin. Pharmacol 60:575–81
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. (1997). Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 62:348–54
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. (2009). Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 31:286–98
   PubMed Web of Science ®Google Scholar
• Kumar V, Rock DA, Warren CJ, et al. (2006). Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos Biol Fate Chem 34:1903–8
   PubMed Web of Science ®Google Scholar
• Lee HS, Jin CB, Chong HS, et al. (1994). Involvement of P4503A in the metabolism of 7,8-benzoflavone by human liver microsomes. Xenobiotica Fate Foreign Compd Biol Syst 24:1053–62
   PubMed Web of Science ®Google Scholar
• Lipscomb JC, Poet TS. (2008). In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol Ther 118:82–103
   PubMed Web of Science ®Google Scholar
• Locuson CW, Wienkers LC, Jones JP, Tracy TS. (2007). CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos Biol Fate Chem 35:1174–81
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. (2000). Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 28:1327–34
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Kantola T, Kivistö KT. (1998). Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol. Ther 63:332–41
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Usuki E, Yerino P, Parkinson A. (2008). In Vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the tabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug–drug interactions. New York: Informa Healthcare, 231–358
   Google Scholar
• Parmentier Y, Bossant MJ, Bertrand M, Walther B. (2007). In vitro studies of drug metabolism. Chem Mol Sci Chemical Eng 5:231–57
   Google Scholar
• Patki KC, Von Moltke LL, Greenblatt DJ. (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos Biol. Fate Chem 31:938–44
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39:99–112
   PubMed Web of Science ®Google Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151–78
   PubMed Web of Science ®Google Scholar
• Raungrut P, Uchaipichat V, Elliot DJ, et al. (2010). In vitro-in vivo extrapolation predicts drug–drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J. Pharmacol Exp Ther 334:609–18
   PubMed Web of Science ®Google Scholar
• Rowland M, Matin SB. (1973). Kinetics of drug–drug interactions. J Pharmacokinet Biopharm 1:553–67
   Google Scholar
• Sheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–12
   PubMedGoogle Scholar
• Stresser DM, Broudy MI, Ho T, et al. (2004). Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos Biol Fate Chem 32:105–12
   PubMed Web of Science ®Google Scholar
• Suzuki A, Iida I, Hirota M, et al. (2003). CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet 18:104–13
   PubMedGoogle Scholar
• Tateishi T, Ohashi K, Sudo T, et al. (1989). Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 29:994–7
   PubMed Web of Science ®Google Scholar
• Tayrouz Y. (2001). Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 70:405–14
   PubMed Web of Science ®Google Scholar
• Troost J, Tatami S, Tsuda Y, et al. (2011). Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 72:247–56
   PubMed Web of Science ®Google Scholar
• Tseng E, Walsky RL, Luzietti RA, et al. (2014). Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 42:1163–73
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Moltke LLV, Greenblatt DJ. (1998). Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502–7
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Harmatz JS, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493–504
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. Biol. Fate Chem 32:647–60
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Liu N, et al. (2000). Human cytochrome P-450 3A4: in vitro drug–drug interaction patterns are substrate-dependent. Drug Metab. Dispos. Biol. Fate Chem 28:360–6
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Stevens J. (2003). Cytochrome P450 reaction phenotyping. In: Lee J, Scott Obach R, Fisher MB, eds. Drug metabolizing enzymes: cytochrome P450 and other enzymes in drug discovery and development. London: CRC Press – Taylor and Francis group,, 255–310
   Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–33
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Urano T, Hiroki S, Shimada T. (1996). Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J Toxicol Sci 21:215–26
   PubMedGoogle Scholar
• Yamazaki H, Inoue K, Turvy CG, et al. (1997). Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos Biol Fate Chem 25:168–74
   PubMed Web of Science ®Google Scholar
• Zimmerlin A, Trunzer M, Faller B. (2011). CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos Biol Fate Chem 39:1039–46
   PubMed Web of Science ®Google Scholar